A Comparative Study of Efficacy and Safety among Metformin, Sitagliptin, and Glimepiride Monotherapies in Patients with Type 2 Diabetes Mellitus
Abstract
Effective management of type 2 diabetes mellitus (T2DM) requires lifestyle changes and suitable medications to enhance quality of life and prevent complications. Choosing the right treatment involves considering the patient's clinical profile, drug efficacy, side effects, and cost. This study compares the safety and efficacy of sitagliptin, glimepiride, and metformin in T2DM patients. A prospective cross-sectional study was conducted at the Diabetes Center of Layla Qasim, Erbil, Iraq, including 143 diabetic patients. They were divided into three groups: group A received glimepiride (N=50), group B metformin (N=48), and group C sitagliptin (N=45). Drug costs, therapeutic outcomes, and side effects were analyzed. Patients aged 30 to 78 participated, with a female-to-male ratio of 83:60. All groups showed significantly improved HbA1c levels (P=0.001). Total cholesterol (TC) and LDL levels were also significantly different (P=0.047 and P=0.010, respectively). Sitagliptin significantly increased triglycerides (TG) and HDL-C. Gastrointestinal side effects were prominent in the metformin group. When selecting medication for T2DM, factors like age, HbA1c, glucose levels, obesity, metabolic syndrome, insulin secretion, and hypoglycemia risk should be considered. Both sitagliptin and glimepiride were well tolerated, with minimal hypoglycemia risk and no significant weight differences between groups. Glimepiride is an effective, safe, and weight-neutral adjunct to metformin, offering extrapancreatic benefits and remains a viable second-line treatment option for T2DM patients.
Downloads
References
H. Wang, J. Kuang and Y. Luo. Insulin sensitivity and pancreatic islet in patients with newly diagnosed type 2 diabetes mellitus. α and β Effect of cell function. Chinese Journal of Diabetes, vol. 12, pp. 382-386, 2020.
R. Hwaiz and H. Sabri. Inhibition of Rac 1 protect against platelet induced liver and kidney injury in diabetes mellitus. Cihan University-Erbil Scientific Journal, vol. 7, no. 1, pp. 29-34, 2023.
A. Hussein, R. Salahalddin, Z. Taha, H. Majeed, A. Muhialdin and R. Faraj. A comparison of chemical compounds between antidiabetic drug and some medicinal plants. Cihan University-Erbil Scientific Journal, vol. 6, no. 2, pp. 99-102, 2022.
S. R. Choudhury, A. Datta and S. Chanda. Overview of current and upcoming strategies implied for the therapy of type 2 diabetes mellitus. Current Diabetes Reviews, vol. 10, pp. 275-282, 2014.
E. Montanya and G. Sesti. A review of efficacy and safety data regarding the use of liraglutide. Diabetes Care, vol. 32, pp. 193- 203, 2009.
W. A. Nuffer and J. M. Trujillo. Liraglutide: A new option for the treatment of obesity. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol. 35, no. 10, pp. 926-934, 2015.
A. J. Scheen and N. Paquot. Gliptin versus a sulphonylurea as add-on to metformin. Lancet (London, England), vol. 380, no. 9840, pp. 450-452, 2012.
N. M. Pham, V. V. Do and A. H. Lee. Polyphenol-rich foods and risk of gestational diabetes: A systematic review and meta-analysis. European Journal of Clinical Nutrition, vol. 73, pp. 647-656, 2019.
B. Viollet, B. Guigas, N. S. Garcia, J. Leclerc, M. Foretz and F. Andreelli. Cellular and molecular mechanisms of metformin: An overview. Clinical Science, vol. 122, no. 6, pp. 253-270, 2012.
E. Sanchez-Rangel and S. E. Inzucchi. Metformin: Clinical use in type 2 diabetes. Diabetologia, vol. 60, pp. 1586-1593, 2017.
I. Vardarli, E. Arndt, C. F. Deacon, J. J. Holst and M. A. Nauck. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and ‘isoglycemic’ intravenous glucose. Diabetes, vol. 63, no. 2, pp. 663-674, 2014.
R. Mahaseth. Incretin system: Recent advances in glucagon like peptide-1 and dipeptidyl peptidase-4 inhibitors. Journal of Patan Academy of Health Sciences, vol. 1, no. 1, pp. 36-42, 2014.
M. Elashoff, A. V. Matveyenko, B. Gier, R. Elashoff and P. C. Butler. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology, vol. 141, pp. 150- 156, 2011.
S. Kalra, S. Bahendeka, R. Sahay, S. Ghosh, M. Fariduddin, A. Orabi, K. Ramaiya, S. Al Shammari, D. Shrestha, K. Shaikh, S. Abhayaratna, P. K. Shrestha, A. Mahalingam, M. Askheta, A. A. A. Rahim., A. K. Das. Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus - International Task Force. Indian Journal of Endocrinology and Metabolism, vol. 22, pp. 132-157, 2018.
M. Anjoom, S. B. Dutta, M. Beg, A. Varma, S. Bawa and R. Kant. Comparative evaluation of combination of metformin and glimepiride with that of metformin and sitagliptin in type 2 diabetes mellitus with respect to glycemic targets. International J of Medical Science and Public Health, vol. 4, no. 4, pp. 476-480, 2015.
N. Mahmood, R. Yahya and S. Aziz. Apply binary logistic regression model to recognize the risk factors of diabetes through measuring glycated hemoglobin levels. Cihan University-Erbil Scientific Journal, vol. 6, no. 1, pp. 7-11, 2022.
D. Rahelic. 7th edition of IDF diabetes atlas: Call for immediate action. Lijec Vjesn, vol. 138, pp. 57-58, 2016.
A. Pan, Y. Wang, M. Talaei, F. B. Hu and T. Wu. Relation of active, passive, and quitting smoking with incident type 2 diabetes: A systematic review and meta-analysis. The Lancet Diabetes and Endocrinology, vol. 3, pp. 958-967, 2015.
C. Baker, C. Retzik-Stahr, V. Singh, R. Plomondon, V. Anderson and N. Rasouli. Should metformin remain the first-line therapy for treatment of type 2 diabetes? Therapeutic Advances in Endocrinology and Metabolism, vol. 12, pp. 1-13, 2021.
T. Xu, S. Brandmaier, A. C. Messias, C. Herder, H. H. M. Draisma, A. Demirkan, Z. Yu, J. S. Ried, T. Haller, M. Heier,…& R. Wang- Sattler. Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes. Diabetes Care, vol. 38, pp. 1858-1867, 2015.
B. M. Makkar, D. Gupta and A. Gainda. Clinical trials to clinical practice: Role of sulfonylureas in today’s practice. In: Medicine Update. Jaypee Brothers Medical Publishers, New Delhi, India, pp. 393-8, 2013.
H. Thacker, S. Shah, M. Chadha, R. Kovil, M. Chawla, S. Gupta and N. Wadhwa. Management of type 2 diabetes in Western India: Attitudes and practices among physicians leading the forefront of diabetes care. Diabetes, vol. 65, pp. A556, 2016.
V. J. Briscoe, M. L. Griffith and S. N. Davis. The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opinion on Drug Metabolism and Toxicology, vol. 6, pp. 225-235, 2010.
D. V. Rados, L. C. Pinto, L. R. Remonti, C. B. Leitão and J. L. Gross. The association between sulfonylurea use and all cause and cardiovascular mortality: A meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med, vol. 13, p. e1001992, 2016.
S. R. Salpeter, E. Greyber, G. A. Pasternak and E. E. Salpeter. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: Systematic review and meta- analysis. Archives of Internal Medicine, vol. 163, pp. 2594, 2003.
H. J. Kim. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clinical Endocrinology. (Oxford), vol. 66, no. 2, pp. 282, 2007.
H. Sakura, N. Hashimoto, K. Sasamoto, H. Ohashi, S. Hasumi, N. Ujihara, T. Kasahara, O. Tomonaga, H. Nunome, M. Honda and Y. Iwamoto. Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: The JAMP study. BMC Endocrine Disorders, vol. 16, no. 70, pp. 1-11, 2016.
Y. wamoto, N. Tajima and T. Kadowaki. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: A randomized, double-blind trial. Diabetes, Obesity and Metabolism, vol. 12, pp. 613-622, 2010.
A. J. Tremblay, B. Lamarche, C. F. Deacon, S. J. Weisnagel and P. Couture. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, vol. 13, no. 4, pp. 366-373, 2011.
N. T. Y. Alibrahim, M. G. Chasib, S. S. H. Hamadi and A. A. Mnsour. Predictors of metformin side effects in patients with newly diagnosed Type 2 Diabetes Mellitus. Ibnosina Journal of Medicine and Biomedical Science, vol. 15, no. 2, pp. 67-73, 2023.
M. Siavash, M. Tabbakhian, A. M. Sabzghabaee and N. Razavi. Severity of gastrointestinal side effects of metformin tablet compared to metformin capsule in type 2 diabetes mellitus patients. Journal of Research in Pharmacy Practice, vol. 6, no. 2, pp. 73-76, 2017.
L. J. McCreight, C. J. Bailey and E. R. Pearson. Metformin and the gastrointestinal tract. Diabetologia, vol. 59, pp. 426-35, 2016.
M. Rani, S. Yadav, S. Choudhary, S. Sharma and S. M. Pandey. Incidence of hypoglycemia and other side effects in patients of type 2 diabetes mellitus treated with glimepiride versus glibenclamide. International Journal of Health Sciences and Research, vol. 4, no. 2, pp. 68-72, 2014.
K. Pranarka, A. Setiawati, S. Halim, D. Saraswati and Z. Alkaf. Glimepiride monotherapy in achieving good blood glucose control in type-2 diabetes mellitus: A prospective observational study. Medical Journal of Indonesia, vol. 18, no. 3, pp. 172-180, 2009.
R. Abdulah, T. F. Suwandiman and N. Handayani. Incidence, causative drugs, and economic consequences of drug-induced SJS, TEN, and SJS-TEN overlap and potential drug-drug interactions during treatment: A retrospective analysis at an Indonesian referral hospital. Therapeutic and Clinical Risk Management, vol. 13, pp. 919-925, 2017.
The British Pharmacological Society. Fatal toxic epidermal necrolysis probably related to glimepiride in a patient with a medical history of hypersensitivity to sulfamethoxazole– trimethoprim. British Journal of Clinical Pharmacology, vol. 87, pp. 1591-1593, 2021.
G. Sargın, R. Köse and T. Şentürk. Sitagliptin/metformin related cutaneous leukocyto-clastic vasculitis in a patient with type-2 diabetes mellitus. Journal of Academic Research in Medicine, vol. 10, no. 1, pp. 97-99, 2020.
Copyright (c) 2024 Ali O. Yassen, Asmaa A. Haydar, Mohammed R. Yaseen, Suzan N.A. Alamdar, Muhamed A. Abbas
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License [CC BY-NC-ND 4.0] that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
